Canada’s national pharmacare program is currently at a standstill, as the federal government has not engaged in negotiations with the remaining provinces and territories to finalize agreements. The recent budget did not allocate additional funds to expand the program nationwide, raising concerns about the future of the public drug plan.
Over a year ago, the Canada Pharmacare Act was passed by the Trudeau Liberals, outlining the commitment to establish agreements with all provinces and territories to cover the costs of contraceptive and diabetes medications and devices. While four regions – B.C., Manitoba, P.E.I., and Yukon – signed deals with Ottawa before the federal election, no new agreements have been announced since then.
Health Minister Marjorie Michel revealed that her department is not actively discussing new agreements with other provinces at the moment. Despite ongoing conversations with provinces and territories regarding future steps, no progress has been made in expanding coverage.
Some provinces, such as Ontario, Saskatchewan, and New Brunswick, expressed readiness to engage in discussions with Ottawa. However, Alberta raised concerns about the program’s long-term sustainability and emphasized the importance of determining the covered medications.
Although Nova Scotia indicated interest in restarting talks five months ago, they are yet to receive a response from the federal government. The absence of additional funding in the latest budget has led to speculation that the government may not be fully committed to advancing pharmacare agreements with all regions.
Advocates point out that the current pharmacare deals only cover around 17% of Canadians, highlighting the disparities in accessing essential medications. Concerns about financial sustainability and the lack of clarity surrounding future agreements continue to persist, with critics questioning the government’s dedication to fulfilling its pharmacare promises.